The Association Between Cognition and Histamine-2 Receptor Antagonists in African Americans

Indiana University Bloomington, Bloomington, Indiana, United States
Journal of the American Geriatrics Society (Impact Factor: 4.57). 09/2007; 55(8):1248-53. DOI: 10.1111/j.1532-5415.2007.01270.x
Source: PubMed


To evaluate the association between histamine-2 receptor antagonist (H2A) exposure and incident cognitive impairment in a community-based sample of African Americans.
Five-year longitudinal observational study.
A sample of 1,558 community-dwelling African Americans aged 65 and older with no baseline cognitive impairment living in Indianapolis, Indiana.
Incident cognitive impairment, defined as incident dementia, cognitive impairment without dementia, or poor cognitive performance, as determined using combined cognitive assessments that included the Community Screening Instrument for Dementia, a comprehensive clinical assessment including informant interview, and neuropsychological testing.
Trained interviewers assessed the use of prescription and over-the-counter H2As using in-home inspection of medications and report of participants and informants.
Incident cognitive impairment occurred in 275 (17.7%) participants. After controlling for age, education, baseline cognitive score, the use of anticholinergics, and history of diabetes mellitus and depression, continuous use of H2As was associated with greater risk of incident cognitive impairment than for nonusers (odds ratio=2.42; 95% confidence interval=1.17-5.04).
H2As might be a risk factor for the development of cognitive impairment in African Americans. This finding requires confirmation from future studies.

Download full-text


Available from: Hisham Aljadhey
  • Source
    • "The impact of long-term exposure to medications with anticholinergic medications remains to be sufficiently examined, as in the PAQUID study of community-dwelling elders in southern France.21 Similarly, a recent study by Boustani and colleagues suggests an increased risk of incident cognitive impairment in African-Americans consistently using H-2 receptor antagonists over a five-year observation period.46 This warrants further study into the impact of chronic exposure to anticholinergic medications, the potential for this exposure to influence cognition over time, and the extent of exposure required to induce adverse cognitive outcomes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The cognitive side effects of medications with anticholinergic activity have been documented among older adults in a variety of clinical settings. However, there has been no systematic confirmation that acute or chronic prescribing of such medications lead to transient or permanent adverse cognitive outcomes. Evaluate the existing evidence regarding the effects of anticholinergic medications on cognition in older adults. We searched the MEDLINE, OVID, and CINAHL databases from January, 1966 to January, 2008 for eligible studies. Studies were included if the anticholinergic activity was systematically measured and correlated with standard measurements of cognitive performance. Studies were excluded if they reported case studies, case series, editorials, and review articles. We extracted the method used to determine anticholinergic activity of medications and its association with cognitive outcomes. Twenty-seven studies met our inclusion criteria. Serum anticholinergic assay was the main method used to determine anticholinergic activity. All but two studies found an association between the anticholinergic activity of medications and either delirium, cognitive impairment or dementia. Medications with anticholinergic activity negatively affect the cognitive performance of older adults. Recognizing the anticholinergic activity of certain medications may represent a potential tool to improve cognition.
    Preview · Article · Feb 2009 · Clinical Interventions in Aging
  • Source

    Preview · Article · May 2009 · Clinical Interventions in Aging
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: This guideline provides evidence-based recommendations on managing hoarseness (dysphonia), defined as a disorder characterized by altered vocal quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related quality of life (QOL). Hoarseness affects nearly one-third of the population at some point in their lives. This guideline applies to all age groups evaluated in a setting where hoarseness would be identified or managed. It is intended for all clinicians who are likely to diagnose and manage patients with hoarseness.
    Full-text · Article · Sep 2009 · Otolaryngology Head and Neck Surgery
Show more